QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: How National Marketing Authorisation Procedures Work in the EU

Test your understanding of the concepts covered by How National Marketing Authorisation Procedures Work in the EU.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best captures the relationship between national authorities and Union coordination mechanisms?

National authorities must choose between exercising national powers and participating in Union mechanisms National authorities can grant or maintain national authorisations while also contributing to EU committees, procedures, inspections and pharmacovigilance National authorities participate in Union mechanisms only after transferring all national authorisations to EMA Union coordination eliminates the need for national competent authorities

Question 2 of 10 What is the defining starting condition for a mutual recognition procedure?

No participating Member State has any relevant national authorisation An existing national marketing authorisation is available to form the basis for recognition A centralised marketing authorisation has already been granted The product must already be authorised in every Member State

Question 3 of 10 Which statement best describes the pharmacovigilance implications of national authorisation?

Nationally authorised medicines are outside the EU pharmacovigilance framework Only centrally authorised products require a functioning pharmacovigilance system Nationally authorised medicines remain subject to the EU pharmacovigilance framework and may contribute to Union-level safety assessment Pharmacovigilance responsibility transfers entirely from the marketing authorisation holder to the NCA

Question 4 of 10 Which statement about product information for nationally authorised medicines is most accurate?

Nationally authorised medicines have no legally relevant product information All nationally authorised medicines use exactly the same documentation architecture as centrally authorised medicines Nationally authorised medicines have authorised product information maintained within the relevant national framework, with harmonisation depending on the procedure and applicable law Product information is maintained solely by the marketing authorisation holder without regulatory oversight

Question 5 of 10 A safety-related change is proposed for a product authorised through MRP in several Member States. Why might the regulatory consequences differ from those for a purely national product?

MRP products are exempt from post-authorisation maintenance The MRP product may require coordination among the relevant Member States, whereas a purely national product principally involves its national competent authority Purely national products cannot have safety-related changes MRP products must always be transferred to the centralised procedure

Question 6 of 10 What is the defining starting condition for a decentralised procedure?

The product already has a national authorisation in the RMS The product already has a centralised Union authorisation The applicant seeks authorisation simultaneously in participating Member States where the relevant national authorisation does not yet exist The product is being converted from a national authorisation into a Union authorisation

Question 7 of 10 A company applies for a medicinal product in only one Member State and does not seek authorisations in other Member States through a coordinated procedure. Which route best describes this situation?

A purely national procedure A mutual recognition procedure A decentralised procedure The centralised procedure

Question 8 of 10 A company claims that DCP creates one authorisation valid identically across all participating countries. What is the most accurate response?

Correct; the RMS becomes the single licensing authority Correct only for products available without prescription Incorrect; DCP coordinates assessment but results in national marketing authorisations in the participating Member States Incorrect because DCP results only in a scientific opinion with no national authorisations

Question 9 of 10 A regulatory team describes a nationally authorised medicine as having a lower scientific standard than a centrally authorised medicine solely because it was assessed by a national authority. What is the most appropriate correction?

The statement is correct because only the centralised procedure applies EU standards The statement is incorrect because the route allocates responsibilities, while common substantive EU requirements still apply The statement is correct unless the product is authorised in more than one Member State The statement is irrelevant because national authorities do not assess benefit-risk

Question 10 of 10 A company uses an existing national authorisation in Member State A to seek authorisations for the same product in Member States B and C. Which interpretation is most accurate?

This is a DCP because several Member States are involved This is an MRP, with Member State A potentially acting as RMS This is automatically the centralised procedure This remains purely national in all three Member States

Knowledge Assessment: How National Marketing Authorisation Procedures Work in the EU

Cookie Settings